Open AccessRecent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer’s and Parkinson’s Diseases
Author(s) -
Sonia Mayo,
Julián BenitoLeón,
Carmen PeñaBautista,
Miguel Baquero,
Consuelo CháferPericás
Publication year - 2021
Publication title -
current neuropharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.955
H-Index - 73
eISSN - 1875-6190
pISSN - 1570-159X
DOI - 10.2174/1570159x19666201223154009
Subject(s) - proteomics , epigenomics , biomarker , medicine , bioinformatics , disease , epigenetics , quantitative proteomics , dementia , neuroinflammation , glial fibrillary acidic protein , pathology , dna methylation , biology , gene expression , genetics , gene , immunohistochemistry
Alzheimer's (AD) and Parkinson's diseases (PD) show deposits of improperly folded modified proteins. Protein expression mechanisms are involved since the early stages. Several studies evaluated epigenomics and proteomics profiles in these patients, with promising results. In general, they focused on early, specific, and minimally invasive biomarkers for the diagnosis and prognosis of AD and PD.